About Me
Conditions and Treatments
Conditions
- astigmatism
- blepharitis
- cataract
- conjunctivitis
- corneal disease
- dry eye syndrome
- eye floater
- eye redness
- glaucoma
- hyperopia
- myopia
- ocular herpes
- presbyopia
- refractive error
- stye
- uveitis
Treatments
- eye surgery
Learn more about conditions we treat at NYU Langone:
Cataract , Conjunctivitis , Dry Eye Syndrome , Glaucoma , Refractive Error , StyeCredentials
Positions
- Clinical Assistant Professor, Department of Ophthalmology at NYU Grossman School of Medicine
Board Certifications
- American Board of Ophthalmology - Ophthalmology, 2013
Education and Training
- Fellowship, NA, Corneal Disease, 2013
- Residency, NYU Langone Medical Center, Ophthalmology, 2012
- MD from Northwestern University, 2008
Is this your profile?
Edit profileInsurance Plans Accepted
This provider accepts the following insurance plans.
-
Aetna
- Aetna HMO
- Aetna Indemnity
- Aetna Medicare
- Aetna POS
- Aetna PPO/EPO
-
Cigna
- Cigna EPO/POS
- Cigna PPO
-
Empire Blue Cross Blue Shield
- Empire Blue Cross Blue Shield EPO
- Empire Blue Cross Blue Shield HMO
- Empire Blue Cross Blue Shield Indemnity
- Empire Blue Cross Blue Shield MediBlue
- Empire Blue Cross Blue Shield POS
- Empire Blue Cross Blue Shield PPO
- Empire Blue Cross Blue Shield Pathways, Enhanced
-
HIP
- HIP Access I
- HIP Access II
- HIP Child Health
- HIP EPO/PPO
- HIP HMO
- HIP Medicare
- HIP POS
-
Local 1199
- Local 1199 PPO
-
MagnaCare
- MagnaCare PPO
-
MultiPlan/PHCS
- MultiPlan/PHCS PPO
-
NYS Health Insurance Plan
- The Empire Plan
-
Oxford
- Oxford Freedom
- Oxford Liberty
- Oxford Medicare
-
UHC
- UnitedHealthcare EPO
- UnitedHealthcare HMO
- UnitedHealthcare Medicare
- UnitedHealthcare POS
- UnitedHealthcare PPO
- UnitedHealthcare Top Tier
Locations and Appointments
Madison Ophthalmology PLLC
161 Madison Avenue, Suite 5SE, New York, NY 10016
Research Academic Contact
Academic office
161 Madison Avenue, Suite 5-SE
New York, NY 10016
Phone
212-448-0101
Fax
212-448-0116
Clinical Trials and Research Studies
-
A Phase 3 Open-Label Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Push Compared with Intravenous Amivantamab or Subcutaneous Amivantamab Administered via On Body Delivery System in Patients with EGFR-Mutated Advanced or Metastatic Non-Small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy.
-
A Phase 1 Open-Label Multicenter Study to Assess Safety Tolerability PK and Efficacy of MK-1084 as Monotherapy and in Combination With Pembrolizumab in Subjects with KRASG12C Mutant Advanced Solid Tumors
-
A Phase 1a/1b Study of LY3537982 in Patients with KRAS G12C-Mutant Advanced Solid Tumors
Publications
-
Tauber, Jenna; Chinwuba, Ijeoma; Kleyn, David; Rothschild, Michael; Kahn, Jonathan; Thiel, Cassandra L
JAMA ophthalmology. 2019 Oct 01; 137(10):1156-1163
-
Charles, Norman C; Kahn, Jonathan B
Ophthalmic plastic & reconstructive surgery. 2017 May/Jun; 33(3S Suppl 1):S33-S34
-
Suhr, K S; Sperber, L T; Marr, B P; Kahn, J B
JCRS online case reports. 2015; 3(1):8-11